{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:10:44Z","timestamp":1793045444235,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.metabol.2020.154457","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T13:03:47Z","timestamp":1606827827000},"page":"154457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":147,"special_numbering":"C","title":["Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression"],"prefix":"10.1016","volume":"116","author":[{"given":"Nisreen","family":"Nimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Choucair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeneng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Nemet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Gukasyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor L.","family":"Weeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Alkhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Zein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H. Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Fischbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Mark","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooman","family":"Allayee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Dasarathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Gogonea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley L.","family":"Hazen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2020.154457_bb0005","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","article-title":"Epidemiology and natural history of non-alcoholic fatty liver disease","volume":"65","author":"Fazel","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2020.154457_bb0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cld.2015.10.001","article-title":"Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world","volume":"20","author":"Sayiner","year":"2016","journal-title":"Clin Liver Dis."},{"key":"10.1016\/j.metabol.2020.154457_bb0015","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2020.154457_bb0020","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2020.154457_bb0025","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/hep.24268","article-title":"Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality","volume":"53","author":"Younossi","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2020.154457_bb0030","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.yexmp.2014.09.005","article-title":"Alcoholic and non-alcoholic steatohepatitis","volume":"97","author":"Neuman","year":"2014","journal-title":"Exp Mol Pathol."},{"key":"10.1016\/j.metabol.2020.154457_bb0035","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2020.154457_bb0040","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of NAFLD is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154457_bb0045","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/MEG.0b013e328345c8c7","article-title":"Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis","volume":"23","author":"Dasarathy","year":"2011","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.metabol.2020.154457_bb0050","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/hep4.1319","article-title":"Relationship between nonalcoholic fatty liver disease susceptibility genes and coronary artery disease","volume":"3","author":"Brouwers","year":"2019","journal-title":"Hepatol Commun."},{"key":"10.1016\/j.metabol.2020.154457_bb0055","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.metabol.2015.08.018","article-title":"Genetics of nonalcoholic fatty liver disease","volume":"65","author":"Dongiovanni","year":"2016","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2020.154457_bb0060","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1055\/s-0035-1567870","article-title":"Insights from genome-wide association analyses of nonalcoholic fatty liver disease","volume":"35","author":"Kahali","year":"2015","journal-title":"Semin Liver Dis."},{"key":"10.1016\/j.metabol.2020.154457_bb0065","doi-asserted-by":"crossref","first-page":"11088","DOI":"10.3748\/wjg.v21.i39.11088","article-title":"Genetic background in nonalcoholic fatty liver disease: a comprehensive review","volume":"21","author":"Macaluso","year":"2015","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.metabol.2020.154457_bb0070","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0035-1562947","article-title":"The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2","volume":"35","author":"Anstee","year":"2015","journal-title":"Semin Liver Dis."},{"key":"10.1016\/j.metabol.2020.154457_bb0075","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.bpg.2014.07.004","article-title":"Bile acids, obesity, and the metabolic syndrome","volume":"28","author":"Ma","year":"2014","journal-title":"Best Pract Res Clin Gastroenterol."},{"key":"10.1016\/j.metabol.2020.154457_bb0080","first-page":"4","article-title":"Insulin resistance and NAFLD: a dangerous liaison beyond the genetics","author":"Manco","year":"2017","journal-title":"Children (Basel)"},{"key":"10.1016\/j.metabol.2020.154457_bb0085","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.metabol.2010.03.006","article-title":"Plasma metabolomic profile in nonalcoholic fatty liver disease","volume":"60","author":"Kalhan","year":"2011","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2020.154457_bb0090","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/hep.26225","article-title":"Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis","volume":"57","author":"Bechmann","year":"2013","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154457_bb0095","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.metabol.2020.154457_bb0100","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.metabol.2020.154457_bb0105","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2020.154457_bb0110","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nrendo.2014.60","article-title":"Beyond intestinal soap\u2014bile acids in metabolic control","volume":"10","author":"Kuipers","year":"2014","journal-title":"Nat Rev Endocrinol."},{"key":"10.1016\/j.metabol.2020.154457_bb0115","doi-asserted-by":"crossref","first-page":"H272","DOI":"10.1152\/ajpheart.01075.2008","article-title":"Antiatherosclerotic effect of farnesoid X receptor","volume":"296","author":"Mencarelli","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"10.1016\/j.metabol.2020.154457_bb0120","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cmet.2011.11.006","article-title":"TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading","volume":"14","author":"Pols","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.metabol.2020.154457_bb0125","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.metabol.2020.154457_bb0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2009.08.001","article-title":"TGR5-mediated bile acid sensing controls glucose homeostasis","volume":"10","author":"Thomas","year":"2009","journal-title":"Cell Metab."},{"key":"10.1016\/j.metabol.2020.154457_bb0135","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet."},{"key":"10.1016\/j.metabol.2020.154457_bb0140","doi-asserted-by":"crossref","first-page":"460190","DOI":"10.1155\/2015\/460190","article-title":"Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis","volume":"2015","author":"Dongiovanni","year":"2015","journal-title":"Biomed Res Int."},{"key":"10.1016\/j.metabol.2020.154457_bb0145","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet."},{"key":"10.1016\/j.metabol.2020.154457_bb0150","first-page":"159","article-title":"Quantification of bile acids: a mass spectrometry platform for studying gut microbe connection to metabolic diseases","volume":"60","author":"Choucair","year":"2019","journal-title":"J Lipid Res."},{"key":"10.1016\/j.metabol.2020.154457_bb0155","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.30429","article-title":"Modulation of insulin resistance in nonalcoholic fatty liver disease","volume":"70","author":"Khan","year":"2019","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154457_bb0160","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.2337\/dbi18-0024","article-title":"Targeting metabolism, insulin resistance, and diabetes to treat nonalcoholic steatohepatitis","volume":"67","author":"Finck","year":"2018","journal-title":"Diabetes."},{"key":"10.1016\/j.metabol.2020.154457_bb0165","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.metabol.2020.154457_bb0170","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2020.154457_bb0175","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/apt.15035","article-title":"Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD","volume":"49","author":"Caussy","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.metabol.2020.154457_bb0180","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12944-020-1201-6","article-title":"The association of serum total bile acid with non-alcoholic fatty liver disease in Chinese adults: a cross sectional study","volume":"19","author":"Zhang","year":"2020","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.metabol.2020.154457_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151829","article-title":"Bile acids and dysbiosis in non-alcoholic fatty liver disease","volume":"11","author":"Mouzaki","year":"2016","journal-title":"PLOS ONE."},{"key":"10.1016\/j.metabol.2020.154457_bb0190","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41575-020-0264-1","article-title":"Obeticholic acid for the treatment of NASH","volume":"17","author":"Hindson","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"10.1016\/j.metabol.2020.154457_bb0195","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/17474124.2020.1748498","article-title":"Obeticholic acid for the treatment of nonalcoholic steatohepatitis","volume":"14","author":"Shah","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2020.154457_bb0200","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1194\/jlr.R024794","article-title":"Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease","volume":"53","author":"Porez","year":"2012","journal-title":"J Lipid Res."},{"key":"10.1016\/j.metabol.2020.154457_bb0205","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1194\/jlr.M001602","article-title":"FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa\/fa) obese rats","volume":"51","author":"Cipriani","year":"2010","journal-title":"J Lipid Res."},{"key":"10.1016\/j.metabol.2020.154457_bb0210","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/hep.23622","article-title":"Homozygosity for the patatin-like phospholipase-3\/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"51","author":"Valenti","year":"2010","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154457_bb0215","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1432-0436.1989.tb00600.x","article-title":"Distribution of intermediate-filament proteins in the human enamel organ: unusually complex pattern of coexpression of cytokeratin polypeptides and vimentin","volume":"40","author":"Kasper","year":"1989","journal-title":"Differentiation."},{"key":"10.1016\/j.metabol.2020.154457_bb0220","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1038\/s41598-017-05768-1","article-title":"TRIB1 is a positive regulator of hepatocyte nuclear factor 4-alpha","volume":"7","author":"Soubeyrand","year":"2017","journal-title":"Sci Rep."},{"key":"10.1016\/j.metabol.2020.154457_bb0225","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1074\/jbc.M311015200","article-title":"Hepatocyte nuclear factor 4alpha is a central regulator of bile acid conjugation","volume":"279","author":"Inoue","year":"2004","journal-title":"J Biol Chem."}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049520303218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049520303218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:25:48Z","timestamp":1758428748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049520303218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":45,"alternative-id":["S0026049520303218"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2020.154457","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2020.154457","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154457"}}